2013
DOI: 10.1016/j.bcp.2012.11.017
|View full text |Cite
|
Sign up to set email alerts
|

β-Phenylethyl isothiocyanate reverses platinum resistance by a GSH-dependent mechanism in cancer cells with epithelial-mesenchymal transition phenotype

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
39
0

Year Published

2014
2014
2024
2024

Publication Types

Select...
5
3

Relationship

1
7

Authors

Journals

citations
Cited by 50 publications
(39 citation statements)
references
References 42 publications
0
39
0
Order By: Relevance
“…Previous studies have demonstrated that binding of GSH to cisplatin causes the formation of a Pt(GS)2 conjugate which is exported to outside of cancer cells by multidrug resistance-associated proteins (MRPs), thus reducing the level of cellular platinum [9,10]. Consistently, other studies showed that increased GSH level is a major factor associated with cisplatin resistance [11][12][13]. Cysteine is a rate-limiting precursor for GSH synthesis.…”
Section: Introductionmentioning
confidence: 92%
See 1 more Smart Citation
“…Previous studies have demonstrated that binding of GSH to cisplatin causes the formation of a Pt(GS)2 conjugate which is exported to outside of cancer cells by multidrug resistance-associated proteins (MRPs), thus reducing the level of cellular platinum [9,10]. Consistently, other studies showed that increased GSH level is a major factor associated with cisplatin resistance [11][12][13]. Cysteine is a rate-limiting precursor for GSH synthesis.…”
Section: Introductionmentioning
confidence: 92%
“…Cysteine is chemically unstable, and cells normally use the stable cystine as a precursor for GSH synthesis. The xc − system, composed of xCT (the light chain and the active subunit) and F42hc (the heavy chain subunit), is essential in maintaining intracellular cysteine/cystine levels by mediating uptake of cystine [13][14][15]. Therefore, inhibition of xc − would suppress GSH synthesis and consequently overcome GSH mediated resistance to cisplatin.…”
Section: Introductionmentioning
confidence: 98%
“…Cancer cells may become resistant to platinum-based drugs through multiple mechanisms, including an increased ability to repair platinum-induced DNA damage, neutralization of platinum toxicity, and an increase in drug export (38). GSH, the most abundant cellular antioxidant, is important in the promotion of cell survival.…”
Section: Discussionmentioning
confidence: 99%
“…ITCs show synergistic activity when combined with common chemotherapeutic agents like cisplatin, paclitaxel, metformin, Adriamycin, etoposide, vorinostat, and docetaxel [140,[142][143][144]. Combination of BITC or PEITC with cisplatin did not affect DNA platination but enhanced the apoptotic effects by depletion of β-tubulin [141,143].…”
Section: Combination Therapymentioning
confidence: 95%
“…Due to its wide range of cellular targets, ITCs can be utilized for combinatorial therapeutic approaches. Combination of ITCs with conventional chemotherapeutic agents has been tested in preclinical models [19,[139][140][141].…”
Section: Combination Therapymentioning
confidence: 99%